SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank67
3Y CAGR-2.0%
5Y CAGR+4.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-2.0%/yr
Annual compound
5Y CAGR
+4.2%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$34.31M+13.7%
2024$30.16M+82.7%
2023$16.52M-54.7%
2022$36.44M-36.3%
2021$57.18M+104.9%
2020$27.91M+248.0%
2019$8.02M-